Literature DB >> 23042614

Personalized medicine benefits patients in early trials: matching targeted therapies with gene mutations is associated with better outcomes, even in phase 1 studies.

Carrie Printz.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 23042614     DOI: 10.1002/cncr.27843

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  1 in total

1.  Targeting MicroRNAs for personalized cancer therapy.

Authors:  Yiwei Li; Aamir Ahmad; Dejuan Kong; Bin Bao; Fazlul H Sarkar
Journal:  Med Princ Pract       Date:  2013-08-13       Impact factor: 1.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.